Suppr超能文献

印度尼西亚风湿性二尖瓣修复和置换手术的临床转归;与非风湿性病因的比较。

Clinical Outcome of Rheumatic Mitral Valve Repair and Replacement Surgery in Indonesia; A Comparison with Non-Rheumatic Aetiology.

机构信息

Dept. Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta Barat, DKI Jakarta, Indonesia.

Adult Cardiac Surgery Division, Department of Surgery, Faculty of Medicine, Universitas Indonesia/National Cardiovascular Center Harapan Kita, Jakarta Barat, DKI Jakarta, Indonesia.

出版信息

Glob Heart. 2024 Jan 11;19(1):4. doi: 10.5334/gh.1285. eCollection 2024.

Abstract

INTRODUCTION

Mitral valve repair (MVr) has been shown to achieve better outcomes than mitral valve replacement (MVR) in degenerative aetiology. However, that cannot be applied in rheumatic mitral valve disease. Therefore, this study aims to evaluate early and late clinical outcomes and mid-term survival in RHD compared to the non-RHD group and whether mitral valve repair is a better surgical approach in RHD patients.

METHODS

Patients who underwent mitral valve surgery with or without coronary artery bypass grafting were included in this study. All patients were divided into the RHD and non-RHD group by the type of mitral surgery performed. Early and late outcomes were evaluated, and mid-term cumulative survival was reported.

RESULTS

A total of 1382 patients post MV surgeries were included. The 30-day mortality was significantly higher in the RHD group compared to the non-RHD group (8.7% vs. 4.4%, p = 0.003). There was no difference in 30-day mortality between repair and replacement in each respective group. During follow-up (12-54 months), all-cause mortality between RHD and non-RHD groups (16.7% vs. 16.2%) was not different. In the RHD group, the survival of MVr was 85.6% (95% CI 82.0%-88.5%), and MVR was 78.3% (95% CI 75.8%-80.6%), p-value log rank 0.26 However, in the non-RHD group, patients who underwent MVr had better survival than MVR, with cumulative survival of 81.7% (95% CI 72.3%-88.2%) vs. 71.1% (95% CI 56.3%-81.7%) p-value log rank 0.007.

CONCLUSION

Early mortality rate in rheumatic mitral valve surgery was higher than in non-rheumatic valve surgery. Although in rheumatic MV disease MV repair did not show a significant survival advantage over MV replacement, a trend towards more favourable survival in the repair group was observed.

摘要

介绍

在退行性病因中,二尖瓣修复(MVr)的效果优于二尖瓣置换(MVR)。然而,这一方法不适用于风湿性二尖瓣疾病。因此,本研究旨在评估风湿性心脏病(RHD)患者与非风湿性心脏病患者相比,在早期和晚期临床结果以及中期生存率方面的差异,以及二尖瓣修复是否是 RHD 患者更好的手术方法。

方法

本研究纳入了接受二尖瓣手术(伴或不伴冠状动脉旁路移植术)的患者。所有患者根据所行二尖瓣手术类型分为 RHD 组和非 RHD 组。评估早期和晚期结果,并报告中期累积生存率。

结果

共纳入 1382 例行 MV 手术的患者。RHD 组 30 天死亡率明显高于非 RHD 组(8.7% vs. 4.4%,p=0.003)。在每个亚组中,修复组和置换组之间 30 天死亡率无差异。在随访期间(12-54 个月),RHD 组和非 RHD 组的全因死亡率(16.7% vs. 16.2%)无差异。在 RHD 组,MVr 的生存率为 85.6%(95%CI82.0%-88.5%),MVR 为 78.3%(95%CI75.8%-80.6%),p 值对数秩检验为 0.26。然而,在非 RHD 组中,MVr 组的生存情况优于 MVR 组,累积生存率分别为 81.7%(95%CI72.3%-88.2%)和 71.1%(95%CI56.3%-81.7%),p 值对数秩检验为 0.007。

结论

风湿性二尖瓣手术的早期死亡率高于非风湿性瓣膜手术。尽管在风湿性 MV 疾病中,二尖瓣修复并未显示出明显优于二尖瓣置换的生存优势,但修复组的生存情况有更有利的趋势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3592/10786046/5131c5ebf8c4/gh-19-1-1285-g1.jpg

相似文献

2
Improved long-term survival for rheumatic mitral valve repair compared to replacement in the young.
World J Pediatr Congenit Heart Surg. 2013 Apr;4(2):155-64. doi: 10.1177/2150135112474024.
5
Early and Midterm Outcomes of Rheumatic Mitral Valve Repair.
Heart Surg Forum. 2018 Aug 14;21(5):E352-E358. doi: 10.1532/hsf.1978.
7
Long-term results after concomitant mitral and aortic valve surgery: repair or replacement?
Eur J Cardiothorac Surg. 2018 Dec 1;54(6):1085-1092. doi: 10.1093/ejcts/ezy205.
8
A Review of Cardiac Surgical Procedures and Their Outcomes for Paediatric Rheumatic Heart Disease in Western Australia.
Heart Lung Circ. 2023 Nov;32(11):1398-1406. doi: 10.1016/j.hlc.2023.08.012. Epub 2023 Oct 16.
9
Concomitant coronary artery bypass graft and aortic and mitral valve replacement for rheumatic heart disease: short- and mid-term outcomes.
Interact Cardiovasc Thorac Surg. 2015 Sep;21(3):322-8. doi: 10.1093/icvts/ivv132. Epub 2015 May 29.

本文引用的文献

1
Impact of Rheumatic Process in Left and Right Ventricular Function in Patients with Mitral Regurgitation.
Glob Heart. 2023 Mar 17;18(1):15. doi: 10.5334/gh.1192. eCollection 2023.
3
Contemporary prevalence and outcomes of rheumatic mitral valve surgery.
J Card Surg. 2022 Jul;37(7):1868-1874. doi: 10.1111/jocs.16369. Epub 2022 Feb 26.
4
Meta-Analysis of Mitral Valve Repair Versus Replacement for Rheumatic Mitral Valve Disease.
Heart Lung Circ. 2022 May;31(5):705-710. doi: 10.1016/j.hlc.2021.11.011. Epub 2022 Feb 1.
5
Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease.
N Engl J Med. 2022 Jan 20;386(3):230-240. doi: 10.1056/NEJMoa2102074. Epub 2021 Nov 13.
6
2021 ESC/EACTS Guidelines for the management of valvular heart disease.
Eur Heart J. 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395.
7
Mitral Valve Surgery in Patients With Rheumatic Heart Disease: Repair vs. Replacement.
Front Cardiovasc Med. 2021 May 28;8:685746. doi: 10.3389/fcvm.2021.685746. eCollection 2021.
8
Cost-utility analysis of heart surgeries for young adults with severe rheumatic mitral valve disease in India.
Int J Cardiol. 2021 Sep 1;338:50-57. doi: 10.1016/j.ijcard.2021.05.059. Epub 2021 Jun 4.
9
Mitral valve repair versus replacement in patients with rheumatic heart disease.
J Thorac Cardiovasc Surg. 2022 Jul;164(1):57-67.e11. doi: 10.1016/j.jtcvs.2020.07.117. Epub 2020 Aug 29.
10
Echocardiography Screening for Latent Rheumatic Heart Disease: What Can We Do in Indonesia?
Front Surg. 2020 Aug 19;7:46. doi: 10.3389/fsurg.2020.00046. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验